Anna Mc Laughlin, Dr. rer.nat.
Consultant
Bio
- Joined Pharmetheus in 2022, actively working in client projects
- Expertise includes model-informed drug development, model-informed precision dosing, and pharmacometrics in therapeutic areas such as oncology, immuno-oncology, and virology
- Previously worked as Senior Scientist at Freie Universitaet Berlin, Germany, where she performed pharmacometric research in therapeutic areas such as oncology and immuno-oncology
- Pharmacist (2017) and Dr.rer.nat. in Pharmacometrics (2021) from Freie Universitaet Berlin, Germany
Pharmetheus affiliated publications
Development of efficient CAR-T cell clinical study designs: Towards understanding of novel anticancer therapies through optimal experimental designA Bayesian-NLME approach identifies patients at risk of delayed MTX elimination if informative TDM data is providedExposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancerModel-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2Population pharmacokinetic analysis of Datopotamab deruxtecan (Dato-DXd), a TROP2-targeting antibody-drug conjugateA circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with Hepatitis DExploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modelingModel-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modelingPotential strategies to optimize CAR-T cell exposure in absence of dose-exposure relationships leveraging cell kinetic/dynamic models